Furthermore, brentuximab vedotin is an anti-CD30 antibody–drug combination that has been licensed for the treatment of CD30-positive lymphoid malignancies, such as Hodgkin’s lymphoma, anaplastic large cell lymphoma, and cutaneous CD30-positive lymphoproliferative diseases. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.